Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
Milestone® (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its ...
Future Market Insights3d
Ophthalmic Eye Drop Market to Reach USD 25,876.4 Million by 2034, Expanding at a CAGR of 4.7%
The global ophthalmic eye drop market is poised for steady growth over the next decade. The market, which was valued at USD ...
With Buyout Interest, Bausch + Lomb May Still Be Worth Interest At Current Levels
Bausch + Lomb has a pretty solid balance sheet that hasn’t changed a lot in the last few quarters. Read why I remain bullish ...
Bausch & Lomb Sues Competition Over Copycat Formulation and 'Confusingly Similar' Product Name
This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.
Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely
Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap ...
Bausch + Lomb Stock Jumps Amid Reports Of A Sale
Bausch + Lomb shares popped following a report that the eyecare company is considering selling itself, to separate from its ...
AOL7d
Why Bausch + Lomb Rallied Today
Shares of Bausch + Lomb (NYSE: BLCO) rallied 15.7% as of 3:07 p.m. ET today. The stock is surging today on news the company is considering selling itself. Of note, Bausch + Lomb is the eye-care ...